EGRX News and Press, Eagle Pharmaceuticals Inc. From 11/02/21

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. ...

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunit...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor conferences as follows: The presentatio...

Judge rules Eagle Pharmaceuticals' version of the drug does not infringe on two patents held by Par Pharmaceuticals, the unit that produces vasostrict. Expect Eagle to start producing and marketing a generic form of vasostrict to treat low blood pressure in the next few months. Ap...

Piper Sandler has lowered its rating on Endo International (NASDAQ:ENDP) to neutral from overweight after a court ruling determined that Eagle Pharmaceuticals (NASDAQ:EGRX) with its marketing application for Vasopressin did not infringe patents related to the Vasostrict marketed by the c...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled “Formulations of Bendamustine.” Eagle is submitting the ...

-- CAL02 neutralizes toxic virulence effectors (“VEs”) produced by bacteria; VEs play a decisive role in the development of long-term, severe and fatal pneumonia complications -- -- Results of first-in-human 1 clinical trial published in The Lancet Infectious Dis...

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing. For further details see: Endo International: Hires Restructuring...